查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529670

数位生物标记市场规模、份额、趋势分析报告：按类型、按临床业务、按治疗领域、按最终用途、按地区、按细分市场、预测，2024-2030 年

Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile Based Applications), By Clinical Practice, By Therapeutic Area, By End-use (Healthcare Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

数位生物标记市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球数位生物标记市场规模将达到139.7亿美元，2024年至2030年复合年增长率为22.7%。

这种成长的推动因素包括医疗保健相关行动应用程式和设备的普及、人们对各种治疗应用的认识提高、智慧型手机的使用增加以及新型可穿戴技术的推出。根据 2021 年Accenture健康与生命科学体验研究，26% 的美国居民透过采用医疗保健应用程式和设备，获得医疗保健服务的机会得到了改善。

此外，由于 COVID-19 爆发带来的巨大困难，政府机构表示有兴趣开发基于数位生物标记的药物。例如，2022 年 3 月，Astra Zeneca与英国医疗科技公司 Huma Therapeutics 合作，开发用于多种治疗疾病的软体即医疗设备 (SaMD)伴同性应用程式。这些应用程式结合了预测演算法、数位生物标记和现实世界资料。

药物研究成本的上升和相对较低的成功率正在推动数位生物标记（DBM）的快速创建。该领域的DBM将有助于专注于特定的分散临床研究领域，例如早发性阿兹海默症和失智症，从而减少药物开发时间、失败率和成本。根据一家名为 healthxl 的数位解决方案公司的部落格报导，数位医学研究所 (DiME) 最近汇集了礼来 (Eli Lilly)、默克 (Merck) 和百健 (Biogen) 等顶级製药公司，为失智症和阿兹海默症。这样做是为了解决评估新治疗方法对人类的有效性的问题，并减少用于研究和开发新治疗方法的时间和金钱。

世界各地的地方政府正在透过实施意识计划和投资数位健康发展来支持生物标誌物的采用。根据加州大学戴维斯分校医学院2022年发表的报导，加州大学戴维斯分校健康中心实施的数位健康公平计画获得了联邦政府170万美元的资助。这笔联邦资金预计将有助于开发一个区域数位公共卫生平台，该平台可以改善北加州和沙加缅度弱势群体获得医疗保健的机会。

AliveCor Inc.、Empatica, Inc.、Huma 和 VivoSense 等新兴企业正在采取收购、联盟、合作伙伴关係和新产品发布等策略，预计这些策略将在预测期内推动市场成长。例如，2023 年 1 月，数位健康公司 Huma 宣布收购 Alcedis，以扩大其在数位临床试验领域的能力。此次收购的目的是在开发过程的各个阶段开发医疗保健解决方案。

数位生物标誌物市场报告亮点

  • 按类型划分，由于医疗保健用途的新型穿戴装置的出现，穿戴式装置在 2023 年占据最大的市场占有率，达到 39.5%。随着政府当局核准新型可穿戴设备，市场对新型穿戴装置的需求预计将会增加。
  • 根据临床实践，诊断数位生物标记在 2023 年占据最大市场占有率，达到 32.4%。诊断数位生物标记是源自穿戴式装置、行动应用程式和医疗设备等数位技术的健康状况或疾病的量化指标。分析资料、行为、资料、资料和资料报告的资料可以实现早期检测、准确诊断和个人化治疗。这些创新工具透过改善患者治疗结果并促进远端监测和疾病管理，为医疗保健的进步做出了贡献。
  • 按治疗领域来看，由于治疗应用的增加和全球心血管疾病的增加，心血管疾病领域在 2023 年以 19.8% 的份额占据市场主导地位。
  • 以最终用途划分，医疗保健公司在 2023 年占据最大的市场占有率，达到 50.1%。这是因为医疗保健公司致力于将数位测量整合到临床护理和研究中。
  • 北美地区占据主导地位，2023 年收益占有率为 58.4%。这是由于主要市场参与者的强大存在、重要的产品发布以及对研发生物标誌物的投资不断增加。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章数位生物标记市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望。
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 数位生物标记市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章数位生物标记市场：按类型估计和趋势分析

  • 2023 年和 2030 年按类型分類的市场占有率
  • 细分仪表板
  • 按类型分類的全球数位生物标记市场展望
  • 2018-2030年市场规模及预测及趋势分析

第五章数位生物标记市场：临床业务的估计和趋势分析

  • 2023年及2030年按临床业务分類的市场占有率份额
  • 细分仪表板
  • 按临床业务分類的全球数位生物标记市场展望
  • 2018-2030年市场规模及预测及趋势分析

第六章数位生物标记市场：按治疗领域估计和趋势分析

  • 2023 年和 2030 年按治疗领域市场占有率
  • 细分仪表板
  • 按治疗领域分類的全球数位生物标记市场前景
  • 2018-2030年市场规模及预测及趋势分析

第七章数位生物标记市场：最终用户的估计和趋势分析

  • 2023 年和 2030 年按最终用户类型市场占有率
  • 细分仪表板
  • 最终用户的全球数位生物标记市场前景
  • 2018-2030年市场规模及预测及趋势分析

第八章数位生物标记市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 北美：SWOT 分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT 分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT 分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT 分析
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 中东/非洲：SWOT 分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • Company Market Position Analysis, 2023
    • ActiGraph LLC
    • AliveCor Inc.
    • Koneksa
    • Altoida Inc.
    • Amgen Inc.
    • Biogen Inc.
    • Empatica Inc.
    • Vivo Sense
    • IXICO plc
    • Adherium Limited
    • Vivo Sense
    • Neurotrack Technologies, Inc.
    • Aural Analytic
    • Huma Therapeutics
    • Sonde Health, Inc.
    • Clario
    • Imagene AI
    • Brainomix
    • Kinsa Inc.
Product Code: GVR-4-68039-989-3

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13.97 billion by 2030, growing at a CAGR of 22.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising adoption of mobile applications & devices related to healthcare, and rising awareness regarding the wide therapeutic applications, increased utilization of smartphones, and the introduction of novel wearable technologies. According to Accenture Health and Life Sciences Experience Survey in 2021, 26% of the people living in the U.S. experienced enhanced access to healthcare services with the adoption of healthcare applications and devices.

Further, governmental organizations have expressed interest in creating digital biomarker-based medication due to the significant hardship brought on by the Covid-19 outbreak. For instance, in March 2022, AstraZeneca teamed up with UK-based medical technology company Huma Therapeutics to develop Software as a Medical Device (SaMD) companion applications for a range of therapeutic diseases. These applications combined predictive algorithms, digital biomarkers, and real-world data.

The rising cost of drug research, combined with its low relative success rate, is fuelling rapid creation of digital biomarkers (DBMs). DBMs in this field assist in focusing on particular decentralized clinical study areas, including early-onset Alzheimer's or dementia, thereby lowering the time, failure rate of drug development, and cost. According to a blog post by a digital solutions company called healthxl, the Digital Medicine Society (DiME) lately brought together top pharmaceutical companies, including Eli Lilly, Merck, and Biogen, to ascertain a set of core standard digital endpoints for dementia and Alzheimer's disease. This was done to solve the issue of assessing the efficacy of new therapies in human subjects as well as to reduce time & money spent on research and development of new remedies.

Regional governments across the globe are supporting the adoption of biomarkers by conducting awareness programs and investing in the development of digital health. According to an article published by the UC Davis School of Medicine in 2022, the Digital Health Equity Program conducted by UC Davis Health received funding of USD 1.7 million from the federal government. This government funding is expected to contribute to the development of a regional digital public health platform capable of enhancing access to healthcare facilities for vulnerable populations in Northern California and Sacramento.

Emerging players, such as AliveCor Inc, Empatica, Inc., Huma, and VivoSense, are adopting strategies such as acquisitions, collaborations, partnerships, and new product launches is anticipated to drive the market growth over the forecast period. For instance, in January 2023, Huma, a digital health company, announced the acquisition of Alcedis to expand its capabilities in the digital clinical trial space. The goal of this acquisition is to develop healthcare solutions across various stages of development processes.

Digital Biomarkers Market Report Highlights:

  • Based on type, wearables held the largest market share of 39.5% in 2023, owing to the emergence of new wearables for healthcare purposes. It is anticipated that the market demand for new wearable devices is expected to increase because of government authorities approving new wearable devices
  • Based on clinical practice, the diagnosis digital biomarkers held the largest market share of 32.4% in 2023. Diagnosis digital biomarkers are quantifiable indicators of health conditions or diseases, derived from digital technologies such as wearables, mobile apps, and medical devices. They enable early detection, accurate diagnosis, and personalized treatment by analyzing physiological, behavioral, biochemical, imaging, and patient-reported data. These innovative tools contribute to the advancement of healthcare by improving patient outcomes and facilitating remote monitoring and disease management
  • Based on therapeutic area,the cardiovascular disease segment dominated the market with a share of 19.8% in 2023, owing to the growing number of therapeutic applications and increasing incidences of cardiovascular disorders globally
  • Based on end use, the healthcare companies held the largest market share of 50.1% in 2023, owing to the fact that healthcare companies have been working toward integrating digital measurements across the spectrum of clinical care & research
  • North America dominated the market and accounted for a revenue share of 58.4% in 2023, owing to the strong presence of leading market players, significant product launches, and an increase in investments in the R&D biomarkers

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Clinical Practice
    • 1.2.3. Therapeutic Area
    • 1.2.4. End User
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Clinical practice outlook
    • 2.2.3. Therapeutic Area Outlook
    • 2.2.4. End User outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Digital Biomarker Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Digital Biomarker Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Digital Biomarker Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Digital Biomarker Market Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Wearable
      • 4.4.1.1. Wearable market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Mobile based applications
      • 4.4.2.1. Mobile based applications market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Sensors
      • 4.4.3.1. Sensors market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Digital Biomarker Market: Clinical Practice Estimates & Trend Analysis

  • 5.1. Clinical Practice Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Digital Biomarker Market Clinical Practice Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Diagnostic digital biomarkers
      • 5.4.1.1. Diagnostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Monitoring digital biomarkers
      • 5.4.2.1. Monitoring digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Predictive and Prognostic digital biomarkers
      • 5.4.3.1. Predictive and Prognostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others (Safety, Pharmacodynamics/ Response, Susceptibility)
      • 5.4.4.1. Others (Safety, Pharmacodynamics/ Response, Susceptibility) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Digital Biomarker Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Therapeutic Area Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Digital Biomarker Market by Therapeutic Area Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cardiovascular and metabolic disorders (CVMD)
      • 6.4.1.1. Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Respiratory diseases
      • 6.4.2.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Psychiatric disorders
      • 6.4.3.1. Psychiatric disorders market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Sleep & movement disease
      • 6.4.4.1. Sleep & movement disease market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Neurological disorders
      • 6.4.5.1. Neurological disorders market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Musculoskeletal disorders
      • 6.4.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Others (Diabetes, Pain Management)
      • 6.4.7.1. Others (Diabetes, Pain Management) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Digital Biomarker Market: End User Estimates & Trend Analysis

  • 7.1. End User Type Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Digital Biomarker Market by End User Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Healthcare companies
      • 7.4.1.1. Healthcare companies market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Healthcare Providers
      • 7.4.2.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Healthcare Providers
      • 7.4.3.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Others (Patient, caregivers)
      • 7.4.4.1. Others (Patient, caregivers) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Digital Biomarker Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Company Market Position Analysis, 2023
    • 9.3.2. ActiGraph LLC
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. AliveCor Inc.
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Koneksa
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Altoida Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Amgen Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Biogen Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Empatica Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Vivo Sense
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. IXICO plc
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Adherium Limited
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Vivo Sense
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Neurotrack Technologies, Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Aural Analytic
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Huma Therapeutics
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Sonde Health, Inc.
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. Clario
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Product benchmarking
      • 9.3.17.4. Strategic initiatives
    • 9.3.18. Imagene AI
      • 9.3.18.1. Company overview
      • 9.3.18.2. Financial performance
      • 9.3.18.3. Product benchmarking
      • 9.3.18.4. Strategic initiatives
    • 9.3.19. Brainomix
      • 9.3.19.1. Company overview
      • 9.3.19.2. Financial performance
      • 9.3.19.3. Product benchmarking
      • 9.3.19.4. Strategic initiatives
    • 9.3.20. Kinsa Inc.
      • 9.3.20.1. Company overview
      • 9.3.20.2. Financial performance
      • 9.3.20.3. Product benchmarking
      • 9.3.20.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 6 North America digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 7 North America digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 9 U.S digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 10 U.S digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 11 U.S digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Canada digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Canada digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 14 Canada digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 15 Canada digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Mexico digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 14 Mexico digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 15 Mexico digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Europe digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 17 Europe digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 18 Europe digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 19 Europe digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 20 Europe digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 U.K digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 U.K digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 23 U.K digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 24 U.K digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 France digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 France digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 23 France digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 24 France digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Germany digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 26 Germany digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 27 Germany digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 28 Germany digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Denmark digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 30 Denmark digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 31 Denmark digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 32 Denmark digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Italy digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Italy digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 35 Italy digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 36 Italy digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Sweden digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 38 Sweden digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 39 Sweden digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 40 Sweden digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 China digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 47 China digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 48 China digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 49 China digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Japan digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 51 Japan digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 52 Japan digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 53 Japan digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 India digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 India digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 56 India digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 57 India digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 Australia digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 59 Australia digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 60 Australia digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 61 Australia digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 South Korea digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 63 South Korea digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 64 South Korea digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 65 South Korea digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Latin America digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 67 Latin America digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 68 Latin America digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 69 Latin America digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 70 Latin America digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Brazil digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 72 Brazil digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 73 Brazil digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 74 Brazil digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Argentina digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 73 Argentina digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 74 Argentina digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 MEA digital biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 80 MEA digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 81 MEA digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 82 MEA digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 83 MEA digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 South Africa digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 South Africa digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 86 South Africa digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 87 South Africa digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia digital biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia digital biomarkers market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia digital biomarkers market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia digital biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 89 UAE digital biomarker market, by type, 2018 - 2030 (USD Million)
  • Table 90 UAE digital biomarker market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 91 UAE digital biomarker market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 92 UAE digital biomarker market, by end user, 2018 - 2030 (USD Million)
  • Table 93 Kuwait digital biomarker market, by type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait digital biomarker market, by clinical practice, 2018 - 2030 (USD Million)
  • Table 95 Kuwait digital biomarker market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 96 Kuwait digital biomarker market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Digital Biomarker: market outlook
  • Fig. 9 Digital Biomarker competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook.
  • Fig. 12 Digital Biomarker driver impact
  • Fig. 13 Digital Biomarker restraint impact
  • Fig. 14 Digital Biomarker strategic initiatives analysis
  • Fig. 16 Digital Biomarkers Market: By Type Movement Analysis
  • Fig. 17 Wearable market estimates and forecasts, 2018 - 2030
  • Fig. 18 Mobile based applications market estimates and forecasts, 2018 - 2030
  • Fig. 19 Sensors market estimates and forecasts, 2018 - 2030
  • Fig. 20 Others market estimates and forecasts, 2018 - 2030
  • Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis
  • Fig. 22 Diagnostic digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Monitoring digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Predictive and prognostic digital biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others digital biomarker market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis
  • Fig. 27 Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Psychiatric disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Sleep & movement disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis
  • Fig. 35 Healthcare companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Healthcare providers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Payers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Regional outlook, 2023 & 2030
  • Fig. 41 North America digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 42 U.S. digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 43 Canada digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 43 Mexico digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 44 Europe digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 45 U.K. digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 45 France digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 46 Germany digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 45 Spain digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Denmark digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Sweden digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Norway digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 48 Italy digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 49 Sweden digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 50 Asia Pacific digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 51 Japan digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 52 China digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 53 India digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 54 South Korea digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 55 Australia digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 56 Latin America digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 57 Brazil digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 58 Argentina digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 59 MEA digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 60 South Africa digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 61 Saudi Arabia digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 62 UAE digital biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 63 Kuwait digital biomarkers market estimates and forecasts, 2018 - 2030